Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

Charles A. Kunos; Denise Fabian; Tricia Fredericks; Lauren Baldwin; Charles Dietrich; Rachel W. Miller; Frederick R. Ueland

doi:10.3389/fonc.2023.1132135

Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

Charles A. Kunos, Denise Fabian, Tricia Fredericks, Lauren Baldwin, Charles Dietrich, Rachel W. Miller, Frederick R. Ueland

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

Original language	English
Article number	1132135
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1132135
State	Published - 2023

Bibliographical note

Funding Information:
This work was supported by NCI grant P30 CA177558 which supports the Biostatistics and Bioinformatics and the Cancer Research Informatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center.

Publisher Copyright:
Copyright © 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.

Keywords

Appalachia
cervical cancer
hemoglobin
survival
uterine cervix

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2023.1132135

Cite this

@article{b8642d0b0d7944e4ad96b69b200a393d,

title = "Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer",

abstract = "Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.",

keywords = "Appalachia, cervical cancer, hemoglobin, survival, uterine cervix",

author = "Kunos, {Charles A.} and Denise Fabian and Tricia Fredericks and Lauren Baldwin and Charles Dietrich and Miller, {Rachel W.} and Ueland, {Frederick R.}",

note = "Funding Information: This work was supported by NCI grant P30 CA177558 which supports the Biostatistics and Bioinformatics and the Cancer Research Informatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center. Publisher Copyright: Copyright {\textcopyright} 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.",

year = "2023",

doi = "10.3389/fonc.2023.1132135",

language = "English",

volume = "13",

}

TY - JOUR

T1 - Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

AU - Kunos, Charles A.

AU - Fabian, Denise

AU - Fredericks, Tricia

AU - Baldwin, Lauren

AU - Dietrich, Charles

AU - Miller, Rachel W.

AU - Ueland, Frederick R.

N1 - Funding Information: This work was supported by NCI grant P30 CA177558 which supports the Biostatistics and Bioinformatics and the Cancer Research Informatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center. Publisher Copyright: Copyright © 2023 Kunos, Fabian, Fredericks, Baldwin, Dietrich, Miller and Ueland.

PY - 2023

Y1 - 2023

N2 - Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

AB - Introduction: The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy. Methods: Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control. Results: Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables. Discussion: In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

KW - Appalachia

KW - cervical cancer

KW - hemoglobin

KW - survival

KW - uterine cervix

UR - http://www.scopus.com/inward/record.url?scp=85165210815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165210815&partnerID=8YFLogxK

U2 - 10.3389/fonc.2023.1132135

DO - 10.3389/fonc.2023.1132135

M3 - Article

AN - SCOPUS:85165210815

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1132135

ER -

Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this